Ryohei Sasaki

Prof. Ryohei Sasaki

orcid

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 January 2021 in Radiation Oncology
Verified
Journal Article
Open access
PDF file
HKHikaru Kubota
Hikaru Kubota
DMDaisuke Miyawaki
Daisuke Miyawaki
NMNaritoshi Mukumoto
Naritoshi Mukumoto
TITakeaki Ishihara
Takeaki Ishihara
MMMegumi Matsumura
Megumi Matsumura
RSRyohei Sasaki
Ryohei Sasaki
Background: To evaluate factors associated with osteoradionecrosis of the jaw (ORNJ) in patients with head and neck squamous cell carcinoma (HNSCC), focusing on jaw-related dose–volume histogram (DVH) parameters. Methods: We retrospectively reviewed the medical records of 616 patients with HNSCC treated with curative-intent or postoperative radiation therapy (RT) during 2008–2018. Patient-related (age, sex, history of smoking or alcohol use, diabetes mellitus, performance status, pre-RT dental evaluation, pre- or post-RT tooth extraction), tumor-related (primary tumor site, T-stage, nodal status), and treatment-related (pre-RT surgery, pre-RT mandible surgery, induction or concurrent chemotherapy, RT technique) variables and DVH parameters (relative volumes of the jaw exposed to doses of 10 Gy–70 Gy [V10–70]) were investigated and compared between patients with and without ORNJ. The Mann–Whitney U test was used to compare RT dose parameters. Univariate and multivariate Cox regression analyses were used to assess factors associated with ORNJ development. Kaplan–Meier analyses were performed for cumulative ORNJ incidence estimation. Results: Forty-six patients (7.5%) developed ORNJ. The median follow-up duration was 40 (range 3–145) months. The median time to ORNJ development was 27 (range 2–127) months. DVH analysis revealed that V30–V70 values were significantly higher in patients with than in those without ORNJ. In univariate analyses, primary tumor site, pre-RT mandible surgery, post-RT tooth extraction, and V60 > 14% were identified as important factors. In multivariate analyses, V60 > 14% (p = 0.0065) and primary tumor site (p = 0.0059) remained significant. The 3-year cumulative ORNJ incidence rates were 2.5% and 8.6% in patients with V60 ≤ 14% and > 14%, respectively (p < 0.0001), and 9.3% and 1.4% in patients with oropharyngeal or oral cancer and other cancers, respectively (p < 0.0001). Conclusions: V60 > 14% and oropharyngeal or oral cancer were found to be independent risk factors for ORNJ. These findings might be useful to minimize ORNJ incidence in HNSCC treated with curative RT.

10 March 2020 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
TTToshifumi Takeuchi
Toshifumi Takeuchi
KMKisho Mori
Kisho Mori
HSHirobumi Sunayama
Hirobumi Sunayama
ETEri Takano
Eri Takano
Yukiya KitayamaYukiya Kitayama
Yukiya Kitayama
HTHirokazu Tanino
Hirokazu Tanino

1 March 2002 in International Journal of Radiation Oncology, Biology, Physics
Verified
Journal Article
Closed access
RSRyohei Sasaki
Ryohei Sasaki
TSToshinori Soejima
Toshinori Soejima
KKKazushi Kishi
Kazushi Kishi
YIYoshinari Imajo
Yoshinari Imajo
SHSaeko Hirota
Saeko Hirota
KSKazuo Sugimura
Kazuo Sugimura

1 February 2012 in International Journal of Radiation Oncology, Biology, Physics
Verified
Journal Article
Closed access
RSRyohei Sasaki
Ryohei Sasaki
KYKoichi Yasuda
Koichi Yasuda
EAEisuke Abe
Eisuke Abe
NUNobue Uchida
Nobue Uchida
MKMitsuhiko Kawashima
Mitsuhiko Kawashima
SYSyogo Yamada
Syogo Yamada

7 July 2016 in Radiation Oncology
Verified
Journal Article
Open access
PDF file
MNMasao NAKAYAMA
Masao NAKAYAMA
RSRyohei Sasaki
Ryohei Sasaki
Chiaki OginoChiaki Ogino
Chiaki Ogino
TTTsutomu Tanaka
Tsutomu Tanaka
KMKenta Morita
Kenta Morita
AKAkihiko Kondo
Akihiko Kondo
Biological applications of nanoparticles are rapidly increasing, which introduces new possibilities to improve the efficacy of radiotherapy. Here, we synthesized titanium peroxide nanoparticles (TiOxNPs) and investigated their efficacy as novel agents that can potently enhance the effects of radiation in the treatment of pancreatic cancer. TiOxNPs and polyacrylic acid-modified TiOxNPs (PAA-TiOxNPs) were synthesized from anatase-type titanium dioxide nanoparticles (TiO2NPs). The size and morphology of the PAA-TiOxNPs was evaluated using transmission electron microscopy and dynamic light scattering. The crystalline structures of the TiO2NPs and PAA-TiOxNPs with and without X-ray irradiation were analyzed using X-ray absorption. The ability of TiOxNPs and PAA-TiOxNPs to produce reactive oxygen species in response to X-ray irradiation was evaluated in a cell-free system and confirmed by flow cytometric analysis in vitro. DNA damage after X-ray exposure with or without PAA-TiOxNPs was assessed by immunohistochemical analysis of γ-H2AX foci formation in vitro and in vivo. Cytotoxicity was evaluated by a colony forming assay in vitro. Xenografts were prepared using human pancreatic cancer MIAPaCa-2 cells and used to evaluate the inhibition of tumor growth caused by X-ray exposure, PAA-TiOxNPs, and the combination of the two. The core structures of the PAA-TiOxNPs were found to be of the anatase type. The TiOxNPs and PAA-TiOxNPs showed a distinct ability to produce hydroxyl radicals in response to X-ray irradiation in a dose- and concentration-dependent manner, whereas the TiO2NPs did not. At the highest concentration of TiOxNPs, the amount of hydroxyl radicals increased by >8.5-fold following treatment with 30 Gy of radiation. The absorption of PAA-TiOxNPs enhanced DNA damage and resulted in higher cytotoxicity in response to X-ray irradiation in vitro. The combination of the PAA-TiOxNPs and X-ray irradiation induced significantly stronger tumor growth inhibition compared to treatment with either PAA-TiOxNPs or X-ray alone (p < 0.05). No apparent toxicity or weight loss was observed for 43 days after irradiation. TiOxNPs are potential agents for enhancing the effects of radiation on pancreatic cancer and act via hydroxyl radical production; owing to this ability, they can be used for pancreatic cancer therapy in the future.

28 February 2008 in Cancer Science
Verified
Journal Article
Open access
PDF file
RSRyohei Sasaki
Ryohei Sasaki
YSYoko Suzuki
Yoko Suzuki
YYYuko Yonezawa
Yuko Yonezawa
YOYosuke Ota
Yosuke Ota
YOYoshiaki Okamoto
Yoshiaki Okamoto
YMYoshiyuki Mizushina
Yoshiyuki Mizushina
Among the vitamin K (VK) compounds, VK3 exhibits distinct cytotoxic activity in cancer cells and is thought to affect redox cycling; however, the underlying mechanisms remain unclear. Here we demonstrate that VK3 selectively inhibits DNA polymerase (pol) γ, the key enzyme responsible for mitochondrial DNA replication and repair. VK3 at 30 µM inhibited pol γ by more than 80%, caused impairment of mitochondrial DNA replication and repair, and induced a significant increase in reactive oxygen species (ROS), leading to apoptosis. At a lower concentration (3 µM), VK3 did not cause a significant increase in ROS, but was able to effectively inhibit cell proliferation, which could be reversed by supplementing glycolytic substrates. The cytotoxic action of VK3 was independent of p53 tumor suppressor gene status. Interestingly, VK3 only inhibited pol γ but did not affect other pol including human pol α, pol β, pol δ, and pol ɛ. VK1 and VK2 exhibited no inhibitory effect on any of the pol tested. These data together suggest that the inhibition of pol γ by VK3 is relatively specific, and that this compound seems to exert its anticancer activity by two possible mechanisms in a concentration‐dependent manner: (1) induction of ROS‐mediated cell death at high concentrations; and (2) inhibition of cell proliferation at lower concentrations likely through the suppression of mitochondrial respiratory function. These findings may explain various cytotoxic actions induced by VK3, and may pave the way for the further use of VK3. ( Cancer Sci 2008; 99: 1040–1048)